“Forward funding” NIH budget plan would make competing for grants much harder

Early endpoints are a balance of risk and benefit

Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.

October 29, 2025

Vol.51 No.39

Clinical Regulatory News Trials & Tribulations

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).

October 17, 2025

Vol.51 No.38

By Edison T. Liu

News Analysis Regulatory News

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

Bowing to the growing animal rights movement, FDA and NIH have made policy changes to discourage animal testing, instead favoring alternative research models.

October 17, 2025

Vol.51 No.38

By Claire Marie Porter and Jacquelyn Cobb

Podcast The Directors

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.

October 10, 2025

Vol.51 No.37

By Claire Marie Porter and Paul Goldberg

Guest Editorial

Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?

As every non-profit organization knows, it is our obligation to be purpose-driven. Most NPO founders and the people who work for them have been thrown into this space as a result of life experiences. It is our passion rather than a job to simply collect a paycheck.

October 10, 2025

Vol.51 No.37

By Erin Miller

Cancer Policy

NIH announces restrictions on human biospecimen sharing with China and other foreign adversaries

NIH has published a policy that prohibits U.S. researchers and NIH grant recipients working with human biospecimens to share this data with “countries of concern.” That list includes China (including Hong Kong and Macau), Russia, Iran, North Korea, Cuba, and Venezuela.

October 10, 2025

Vol.51 No.37

By Sara Willa Ernst

“Forward funding” NIH budget plan would make competing for grants much harder

YOU MAY BE INTERESTED IN

Early endpoints are a balance of risk and benefit

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?

NIH announces restrictions on human biospecimen sharing with China and other foreign adversaries

Renew today!

Subscriber content

Never miss an issue!

Login

“Forward funding” NIH budget plan would make competing for grants much harder

YOU MAY BE INTERESTED IN

Early endpoints are a balance of risk and benefit

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

How animal testing became a MAHA political wedge issueWhile cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

Lazarex Cancer Foundation set to close its doors Dec. 31Can health nonprofits survive in the current environment?

NIH announces restrictions on human biospecimen sharing with China and other foreign adversaries

Never miss an issue!

Login

How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough

The Directors: Steven Artandi and Eric Winer on how looming policy changes “reverberate” through oncology
“Even when funding gets restored and if the H-1B visa threat doesn’t materialize, it creates an environment where especially young people become uncertain.”

Lazarex Cancer Foundation set to close its doors Dec. 31
Can health nonprofits survive in the current environment?